{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:03:06Z","timestamp":1792094586048,"version":"4.4.0"},"reference-count":49,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Two phase 3 trials, POETYK PSO\u20101 and PSO\u20102, previously established the efficacy and overall safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in plaque psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To further assess the safety of deucravacitinib over 52\u2009weeks in the pooled population from these two trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Pooled safety data were evaluated from PSO\u20101 and PSO\u20102 in which patients with moderate\u2010to\u2010severe plaque psoriasis were randomized 1:2:1 to receive oral placebo, deucravacitinib or apremilast.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1683 patients were included in the pooled analysis. Adverse event (AE) incidence rates were similar in each treatment group, serious AEs were low and balanced across groups, and discontinuation rates were lower with deucravacitinib versus placebo or apremilast. No new safety signals emerged with longer deucravacitinib treatment. Exposure\u2010adjusted incidence rates of AEs of interest with placebo, deucravacitinib and apremilast, respectively, were as follows: serious infections (0.8\/100 person\u2010years [PY], 1.7\/100 PY, and 1.8\/100 PY), major adverse cardiovascular events (1.2\/100 PY, 0.3\/100 PY, and 0.9\/100 PY), venous thromboembolic events (0, 0.2\/100 PY, and 0), malignancies (0, 1.0\/100 PY and 0.9\/100 PY), herpes zoster (0.4\/100 PY, 0.8\/100 PY, and 0), acne (0.4\/100 PY, 2.9\/100 PY, and 0) and folliculitis (0, 2.8\/100 PY, and 0.9\/100 PY). No clinically meaningful changes from baseline in mean levels, or shifts from baseline to CTCAE grade \u22653 abnormalities, were reported in laboratory parameters with deucravacitinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Deucravacitinib was well\u2010tolerated with acceptable safety over 52\u2009weeks in patients with psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.19925","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T13:38:02Z","timestamp":1709818682000},"page":"1543-1554","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Deucravacitinib in moderate\u2010to\u2010severe plaque psoriasis: Pooled safety and tolerability over 52\u2009weeks from two phase 3 trials (<scp>POETYK PSO<\/scp>\u20101 and <scp>PSO<\/scp>\u20102)"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"first","affiliation":[{"name":"Department of Dermatology Yale University  New Haven Connecticut USA"},{"name":"Central Connecticut Dermatology Research  Cromwell Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center  Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre Northern Care Alliance NHS Foundation Trust  Manchester UK"},{"name":"Manchester NIHR Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[{"name":"Alliance Clinical Trials and Probity Medical Research  Waterloo Ontario Canada"},{"name":"Division of Dermatology, Department of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of California Los Angeles  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Dermatology \u2013 Froedtert Cancer Center Medical College of Wisconsin  Milwaukee Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Environmental Dermatology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Alexis","sequence":"additional","affiliation":[{"name":"Department of Dermatology Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Department of Dermatology Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Foley","sequence":"additional","affiliation":[{"name":"Skin Health Institute and Probity Medical Research  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata M.","family":"Kisa","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Colston","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Institute and Comprehensive Centre for Inflammation Medicine University of Luebeck  Luebeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02342"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20060244"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00596-8"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_2_10_12_1","volume-title":"Sotyktu [package insert]","year":"2022"},{"key":"e_1_2_10_13_1","volume-title":"Sotyktu Japan [package insert]","year":"2022"},{"key":"e_1_2_10_14_1","volume-title":"Sotyktu [product monograph]","year":"2022"},{"key":"e_1_2_10_15_1","volume-title":"Sotyktu [product information]","year":"2022"},{"key":"e_1_2_10_16_1","volume-title":"Sotyktu [summary of product characteristics]","year":"2023"},{"key":"e_1_2_10_17_1","volume-title":"Sotyktu [package insert]","year":"2023"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.82"},{"key":"e_1_2_10_21_1","volume-title":"Otezla [package insert]","year":"2021"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03001.x"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.052"},{"key":"e_1_2_10_24_1","unstructured":"Cosentyx (secukinumab) assessment report. Canary Wharf: European Medicines Agency.2014. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/cosentyx\u2010epar\u2010public\u2010assessment\u2010report_en.pdf. Accessed December 21 2022."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15723"},{"key":"e_1_2_10_26_1","unstructured":"Skyrizi CHMP assessment report. London UK: European Medicines Agency.2019. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/skyrizi\u2010epar\u2010public\u2010assessment\u2010report_en.pdf. Accessed December 21 2022."},{"key":"e_1_2_10_27_1","unstructured":"Tremfya (guselkumab) BLA multi\u2010disciplinary review and evaluation.U.S. Food and Drug Administration 2016. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761061Orig1s000MultidisciplineR.pdf. Accessed December 22 2021."},{"key":"e_1_2_10_28_1","unstructured":"Stelara (ustekinumab) assessment report.Canary Wharf: European Medicines Agency 2009. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/stelara\u2010epar\u2010public\u2010assessment\u2010report_en.pdf. Accessed December 21 2022."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.6.719"},{"key":"e_1_2_10_30_1","unstructured":"Humira (adalimumab) scientific discussion Canary Wharf: European Medicines Agency.2007. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010discussion\u2010variation\/humira\u2010h\u2010c\u2010481\u2010ii\u201038\u2010epar\u2010scientific\u2010discussion\u2010variation_en.pdf. Accessed December 21 2022."},{"key":"e_1_2_10_31_1","unstructured":"Cimzia (certolizumab pegol) assessment report.Canary Wharf: European Medicines Agency.2018. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/variation\u2010report\/cimzia\u2010h\u2010c\u20101037\u2010ii\u20100065\u2010epar\u2010assessment\u2010report\u2010variation_en.pdf. Accessed December 21 2022."},{"key":"e_1_2_10_32_1","unstructured":"Siliq (brodalumab) BLA.U.S. Food and Drug Administration.2015. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761032Orig1s000MedR.pdf. Accessed December 21 2022."},{"key":"e_1_2_10_33_1","unstructured":"Ilumya (tildrakizumab) statistical review and evaluation.Silver Spring MD: U.S. Food and Drug Administration.2018. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/761067Orig1s000MultdisciplineR.pdf. Accessed December 21 2022."},{"key":"e_1_2_10_34_1","volume-title":"Xeljanz [package insert]","year":"2022"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(99)70064-8"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.12.7263"},{"key":"e_1_2_10_37_1","volume-title":"Taltz [package insert]","year":"2021"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000942"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018125"},{"key":"e_1_2_10_40_1","first-page":"S376","article-title":"Overview of venous thromboembolism","volume":"23","author":"Phillippe HM","year":"2017","journal-title":"Am J Manag Care"},{"key":"e_1_2_10_41_1","unstructured":"Center for Drug Evaluation and Research.Medical Review of Baricitinib. U.S. Food and Drug Administration.2017. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/207924Orig1s000MedR.pdf. Accessed January 11 2023."},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.09.021"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(02)00351-1"},{"key":"e_1_2_10_44_1","unstructured":"Otezla (apremilast) assessment report . Canary Wharf: European Medicines Agency.2014. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/otezla\u2010epar\u2010public\u2010assessment\u2010report_en.pdf. Accessed December 21 2022."},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1221923"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00512-4"},{"key":"e_1_2_10_47_1","unstructured":"Cancer Facts & Figures\u00a02020. Atlanta GA: American Cancer Society.2020. Available from:https:\/\/www.cancer.org\/content\/dam\/cancer\u2010org\/research\/cancer\u2010facts\u2010and\u2010statistics\/annual\u2010cancer\u2010facts\u2010and\u2010figures\/2020\/cancer\u2010facts\u2010and\u2010figures\u20102020.pdf. Accessed December 21 2022."},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18232"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.024"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T09:09:11Z","timestamp":1732871351000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1111\/jdv.19925"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19925","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"2023-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}